Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.

Dominick J Angiolillo, Davide Capodanno

Journal: Circulation. Cardiovascular interventions 2014;7(1):113-24

PMID: 24550531

Abstract

Address: From the Cardio-thoraco-vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.); and Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, FL (D.C., D.J.A).

DOI: 10.1161/CIRCINTERVENTIONS.113.001150

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://scite.ai/reports/24550531

Subscription / membership required

Full Text Sources:

MeSH Terms: Acute Coronary Syndrome, Adenosine, Administration, Oral, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Dabigatran, Hemorrhage, Humans, Morpholines, Percutaneous Coronary Intervention, Piperazines, Platelet Aggregation Inhibitors, Postoperative Complications, Prasugrel Hydrochloride, Pyrazoles, Pyridones, Rivaroxaban, Thiophenes, Thrombosis, Ticagrelor, beta-Alanine